Literature DB >> 24346924

Allogeneic hematopoietic stem cell transplantation in mycosis fungoides.

Angelo Atalla1, Abrahão Elias Hallack Neto2, Denise Bittencourt Siqueira3, Gabriela Cumani Toledo3.   

Abstract

Mycosis Fungoides is typically an indolent disease in early stages. However, approximately 30% of patients have advanced staged disease at presentation and 20% will develop it at some time. These patients have a poorer prognosis with a median survival of 2-4 years. The only curative option for mycosis fungoides may be hematopoietic allogeneic stem cell transplantation. We report the case of a patient with mycosis fungoides in an advanced stage (IIB), refractory to treatment options. She underwent allogeneic hematopoietic stem-cell transplantation (allo-HSCT). The patient remains in complete remission nineteen months after allo-HSCT. Allogeneic transplantation can alter the natural history of mycosis fungoides and should be considered in patients who have refractory disease or short-lived responses with standard therapies.

Entities:  

Mesh:

Year:  2013        PMID: 24346924      PMCID: PMC3875963          DOI: 10.1590/abd1806-4841.20132365

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  10 in total

Review 1.  Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.

Authors:  Sean J Whittaker; Francine M Foss
Journal:  Cancer Treat Rev       Date:  2007-02-01       Impact factor: 12.111

2.  A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome.

Authors:  Peggy A Wu; Youn H Kim; Phillip W Lavori; Richard T Hoppe; Keith E Stockerl-Goldstein
Journal:  Biol Blood Marrow Transplant       Date:  2009-08       Impact factor: 5.742

3.  Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.

Authors:  Arturo Molina; Jasmine Zain; Daniel A Arber; Maria Angelopolou; Margaret O'Donnell; Joyce Murata-Collins; Stephen J Forman; Auayporn Nademanee
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

4.  A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.

Authors:  E D Jacobsen; H T Kim; V T Ho; C S Cutler; J Koreth; D C Fisher; P Armand; E P Alyea; A S Freedman; R J Soiffer; J H Antin
Journal:  Ann Oncol       Date:  2011-01-20       Impact factor: 32.976

5.  Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Rafael F Duarte; Carmen Canals; Francesco Onida; Ian H Gabriel; Reyes Arranz; William Arcese; Augustin Ferrant; Guido Kobbe; Franco Narni; Giorgio Lambertenghi Deliliers; Eduardo Olavarría; Norbert Schmitz; Anna Sureda
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 6.  Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.

Authors:  Max Schlaak; Juliane Pickenhain; Sebastian Theurich; Nicole Skoetz; Michael von Bergwelt-Baildon; Peter Kurschat
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

7.  Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.

Authors:  R van Doorn; C W Van Haselen; P C van Voorst Vader; M L Geerts; F Heule; M de Rie; P M Steijlen; S K Dekker; W A van Vloten; R Willemze
Journal:  Arch Dermatol       Date:  2000-04

8.  Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology.

Authors:  M A Weinstock; J W Horm
Journal:  JAMA       Date:  1988-07-01       Impact factor: 56.272

9.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.

Authors:  Youn H Kim; Howard L Liu; Serena Mraz-Gernhard; Anna Varghese; Richard T Hoppe
Journal:  Arch Dermatol       Date:  2003-07

Review 10.  Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update.

Authors:  Thamy Yamashita; Luciana Patricia Fernandes Abbade; Mariangela Esther Alencar Marques; Silvio Alencar Marques
Journal:  An Bras Dermatol       Date:  2012 Nov-Dec       Impact factor: 1.896

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.